Pharmaceutical Channel

Personalized Medicine and The Real Life Dangers of Prescription Drugs

 
Dr. Elizabeth Reed Aden, a PHD and a former pharma industry executive and the author of The Goldilock Genome joins eHealth Radio and the Health News and Pharmaceutical Channels.
Listen to interview with host Eric Michaels & guest Dr. Elizabeth Reed Aden discuss the following:
You wrote your book, The Goldilocks Genome, based on your experiences in the pharmaceutical industry. What is it about?
What is "the Goldilocks effect" in prescription drugs?
Why are you a champion of personalized medicine?
Name a few examples of how knowing our personal genetics can help us make better choices in food and medication?
What do you want your readers to take away from your book?  
Elizabeth Reed Aden, PhD earned her doctorate in biomedical anthropology from the University of Pennsylvania. After conducting extensive epidemiology and serology studies and teaching as an Assistant Professor at the University of Illinois, Urbana-Champaign, she began her career in the pharmaceutical industry, where she rose to be Senior Vice President for Global Pharmaceutical Strategy at a major Swiss pharmaceutical company.
After leaving Big Pharma, she held leadership positions in various biotechnology companies, founded and co-founded biotech companies, consulted for a wide range of clients, and served on Boards of Directors. Since 2017, she has brought multiple previously unpublished cozy murder mysteries written by her godmother, Eunice Mays Boyd, to print, among them Dune House, Slay Bells, and A Vacation to Kill For. The Goldilocks Genome is Elizabeth’s debut medical thriller. She is currently working on a memoir, Hepatitis Beach, which she hopes to have published by 2025. She lives in Berkeley, California.
Website: https://elizabethreedaden.com
Social Media Links: Instagram: https://www.instagram.com/elizabeth_r_aden  Facebook: https://www.facebook.com/ElizabethReedAden  Twitter: https://twitter.com/eliz_reed_aden 
People also listened to this: Breast Implant Illness & Implant Removal with Dr. Sayed

Bloop is not your grandmother’s Preparation H

 
 
Amany Mansour-Awad, a compounding pharmacist and the CEO and Founder of Bloop joins eHealth Radio and the Pharmaceutical and Health News Channels.
Listen to interview with host Eric Michaels and guest Amany Mansour-Awad discuss the following:
How has your background as a pharmacist played a role in the product development for Bloop?
What are you aiming to do with the founding and development of Bloop?
How does Bloop compare with the popular Preparation H and other competitors in the industry?
Why is Bloop so effective for the body’s most sensitive parts?
Why is it important for the Bloop brand to show empathy, care, and compassion?
Lastly, can you offer a tip on overcoming challenges for a woman of color in your industry?
Amany Mansour-Awad spent decades in the world of pharmaceutics. She then segued into the pharmacy industry. During her years as the owner of a national compounding pharmacy specializing in the difficult arena of rare disease, Amany saw the suffering caused by colorectal cancer. These experiences inspired her to formulate her own products that could help reduce their suffering.
Despite facing numerous challenges along her entrepreneurial path, including being a single mother and a woman of color who encountered the glass ceiling, she also confronted the battle with a rare blood cancer. However, she persevered through these obstacles and made it her mission to develop topical treatments for sensitive area afflictions. In addition to her dedication to this cause, she serves as the founder and a board member of Chemistry Rx and is a passionate advocate for personal intimate wellness.
Website: https://gotbloop.com 
Social Media Links: Linkedin: https://www.linkedin.com/company/got-bloopTikTok: https://www.tiktok.com/@bloopcareInstagram: https://www.instagram.com/bloopcare
People also listened to this: How Do People with Less Stress Differ from Those with More?

Targeted Radiotherapies for Patients with Unmet Needs: A Conversation with Actinium Pharmaceuticals CEO Sandesh Seth

 
 
Sandesh Seth, CEO of Actinium Pharmaceuticals which is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels and guest Sandesh Seth discuss the following:
What is unique about Actinium’s radiotherapy approach?
Tell me about Iomab-B, its target population, and how it will affect the patient journey.
Actimab-A is also in AML. How is it different from Iomab-B and what’s the approach here?
What’s next in your pipeline?
Tell me what upcoming catalysts I should expect in the second half of 2023.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an induction and conditioning agent prior to bone marrow transplant, and Actimab-A (National Cancer Institute CRADA pivotal development path), a therapeutic, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. Actinium's technology platform is the basis for collaborations with Astellas Pharma for solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3 solid tumors, and EpicentRx for its CD47 targeting agent, and several internal programs in solid tumors. Actinium holds more than 200 patents and patent applications.
Website: https://www.actiniumpharma.com
Social Media Links: Linkedin: https://linkedin.com/company/actinium-pharmaceuticals-inc-Facebook: https://facebook.com/people/Actinium-Pharmaceuticals-IncTwitter: https://twitter.com/ActiniumPharma
People also listened to this: The Miracle of Enzymes to Heal Digestive Problems

Improving the health and well-being of patients affected by Alzheimer’s disease

 
 
Ram Mukunda and Claudia Grimaldi from IGC Pharma, a clinical stage pharmaceutical company focused on improving the health and well-being of patients affected by Alzheimer’s disease and bringing these therapies to market joins eHealth Radio and the Alzheimer’s Information and Health News Channels.
Listen to interview with host Eric Michaels and guests Ram Mukunda and Claudia Grimaldi discuss the following:
Many people are aware of the symptoms of Alzheimer's including dementia, but many are unaware of that agitation is one of the most common and challenging aspects of care among patients with dementia due to Alzheimer’s disease. Can you explain why?
How does this condition affect those caring for a patient affected by Alzheimer's?
How does your investigational drug IGC-AD1 work to help these patients?
What are the next steps in bringing this drug to market?
What other therapies is IGC Pharma working on in Alzheimer’s?
Ram Mukunda is both the founder and Chief Executive Officer of IGC Pharma. Prior to forming IGC Pharma, he was the President, Chief Executive Officer & Director at India Globalization Capital, Inc., Chairman, President & Chief Executive Officer for Techni Bharathi Pvt Ltd. (a subsidiary of India Globalization Capital, Inc.).
Ram Mukunda previously occupied the position of Council Member at Jamaica Dairy Development Board, Chairman & Chief Executive Officer of Startec Global Communications Corp., Council Member at Harvard Kennedy School of Government and Council Member at Belfer Center for Science & International Affairs.
Ram Mukunda received an undergraduate degree and a graduate degree from the University of Maryland.
Claudia Grimaldi has been with IGC for almost 12 years with increasing responsibilities including managing SEC and NYSE filings, regulatory compliance, and disclosures. She is currently Vice President, Principal Finance Officer, and Chief Compliance Officer. She is also the Managing Director of Hamsa Biochem SAS, our subsidiary in Colombia, as well as a director of our subsidiary in India.
Ms. Grimaldi graduated with a BA in Psychology with high honors from Javeriana University, a top three university in Colombia, and an MBA with high honors from Meredith College in North Carolina. She has completed Executive Education courses on SEC compliance, finance from UVA, and corporate governance from the Columbia Business School.
Website: https://www.igcpharma.com 
People also listened to this: Improving skin health is a journey

Biotechnology company developing therapeutic candidates targeting drug-resistant and devastating cancers using ferroptosis

 
 
Randy Milby, the Chief Executive Officer and Chairman of Hillstream BioPharma, a biotechnology company developing therapeutic candidates targeting drug-resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death, and immuno-oncology targeted novel biologics joins eHealth Radio and the Cancer Information & Health News Channels.
Listen to interview with host Eric Michaels and guest Randy Milby discuss the following:
Please tell us a bit about your background and Hillstream BioPharma.
What developments are currently in Hillstream’s pipeline?
How does ferroptosis-targeted therapy differentiate from other cancer treatments currently available or under development?
Why is it important to Hillstream to develop drug resistant therapeutics for cancers with few treatment options?
What advice can you share with industry peers, key opinion leaders, or anyone pursuing R&D in the biotechnology space?
Looking ahead, what exciting advances do you think are on the horizon for Hillstream?
Mr. Milby previously served as Chief Executive Officer and Member of the Board of Directors at CorMedix, a publicly traded biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of inflammatory and infectious diseases. He is a seasoned executive who led the increase in market capitalization from $3M to a peak of $350M of Cormedix while improving the company’s financial position with capital raises from equity markets. He oversaw efforts to gain CE Market approval of Neutrolin® in the European Union and held increasing roles of responsibility at Goldman Sachs and Dupont Merck prior in his career.
 
Website: https://hillstreambio.com 
Social Media Links: Facebook: https://facebook.com/HillstreamBioPharma  Linkedin: https://linkedin.com/company/hillstream-biopharma  Twitter: https://twitter.com/HillstreamB 
People also listened to this: Checkable Medical: Revolutionizing Home Healthcare and Telemedicine

Antisense Therapeutics is bringing bringing life changing innovative medicines to patients with rare diseases

 
 
Mark Diamond, Managing Director and CEO at Antisense Therapeutics Limited joins eHealth Radio and the Health News Channel. Antisense is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases.
Listen to host Eric Dye & guest Mark Diamond discuss the following:
Tell us more about Antisense. How is the company specifically developing treatments for Duchenne muscular dystrophy? Describe who is affected and the number of patients that are potentially seeking treatment.
Antisense conducted a new pre-clinical study. What did that involve, what were some of the results? What’s next?
COVID-19 is a part of many people’s lives. There are a variety of new, returning or ongoing symptoms that people experience more than four weeks after getting COVID-19. Tell us more about that.
Antisense is addressing medical needs and also financial opportunities. Tell us about the size of the market and the opportunities.
What's next for Antisense in 2023 and even in 2024? Where can we find out more?

Mark Diamond has over 30 years experience in the pharmaceutical and biotechnology industry. Before joining Antisense Therapeutics Limited as MD and CEO in 2001, Mr. Diamond was employed in the US as Director, Project Planning/Business Development at Faulding Pharmaceuticals. Prior to this he held the positions of Senior Manager, Business Development and In-licensing within Faulding’s European operation based in the UK and International Business Development Manager with Faulding in Australia.
Website: https://www.antisense.com.au
Social Media Links: Twitter: https://twitter.com/antisenselLinkedin: https://linkedin.com/company/antisense-therapeutics-ltd.
People also listened to this: How to Battle Snoring with The Snorinator

Petros Pharmaceuticals’ Bringing New Treatments to Men’s Health

 
 
Fady Boctor, President and Chief Commercial Officer at Petros Pharmaceuticals, a leading provider of therapeutics for men’s health joins eHealth Radio and the Men's Health and Pharmaceutical Channels.
Listen to interview with host Eric Michaels and guest Fady Boctor discuss the following:
Please give us a bit of background on Petros, its core mission, and how you got started with the company.
What is in your current pipeline of developments?
Please give us a brief overview of the ED market and how Petros aims to bring new treatments to men’s health.

Could you please give us a brief overview of what differentiates Petros from others in the same category?
What recent or upcoming milestones is the company working towards?
Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men's health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health, and substance use disorders.
 
 
Website: https://www.petrospharma.com
Social Media Links: Facebook: https://facebook.com/PetrosPharmaceuticals Linkedin: https://linkedin.com/company/petros-pharmaceuticals Twitter: https://twitter.com/PetrosPharma

AscellaHealth’s Craig Caceci, Executive Vice President and Managing Director, Terebellum

 
Craig Caceci, Executive Vice President and Managing Director of Terebellum, part of AscellaHealth Family of Companies, based in Dublin, Ireland, offering premier pre-commercialization and market access expertise, supply chain logistics and distribution, and unique pharmaceutical financial solutions, such as loan-based assistance to Life Sciences partners and other industry stakeholders joins eHealth Radio and the Health News Channel.
Listen to interview with host Eric Michaels and guest Craig Caceci discuss the following:
Can you give our listeners some background on your work within Terebellum?
The AscellaHealth Family of Companies recently announced Terebellum’ s plans for expansion into Germany and the United Kingdom. Will this expanded international footprint come with any additional services and if yes, will they differ from those offered in the US?
How will this expanded marketplace impact the scope of opportunities now available to pharmaceutical companies and what impact will these services have on lives of patients with complex chronic conditions or rare diseases?
From the specialty drug manufacturers’ perspective, what are the advantages of accessing services from a robust resource that includes pre-commercialization to fulfilment programs with the ability to tailor services to individual unmet needs?
I understand Terebellum has extensive payer expertise within Europe. How does working the Terebellum help ensure seamless product access for patients?
Please explain how Terebellum’s services are offered as both an inclusive package or a la carte.
Craig Caceci, Executive Vice President and Managing Director of Terebellum, part of AscellaHealth Family of Companies. Terebellum is a Dublin, Ireland based subsidiary of AscellaHealth representing AscellaHealth’s global footprint throughout Europe. The premier group purchasing services, unique pharmaceutical financial solutions, payer and market access expertise and custom pull-through programs targeted to Life Sciences partners and other industry stakeholders ensure optimal cost savings and enhanced clinical outcomes. Terebellum’s leadership team has the deep payer, reimbursement, marketing, and financial expertise needed to provide a consultative approach for branded specialty products to be brought to market successfully.
 
Website: https://ascellahealth.com 
Linkedin: https://linkedin.com/company/ascellahealth 

Innovative Market Access and Product Life Cycle Solutions for Life Sciences with AscellaHealth

 
Michael Baldzicki, Chief Brand Officer at AscellaHealth, a global specialty pharmacy and healthcare solutions company joins eHealth Radio and the Healthcare and Pharmaceutical Information Channels to talk about the company’s comprehensive suite of Specialty Pharmacy services for pharmaceutical/biotech manufacturers.
Listen to interview with host Eric Michaels and guest Michael Baldzicki discuss the following:
Can you give our listeners information on your background and role with AscellaHealth?
Please describe the AscellaHealth business model and how the company serves life sciences in the specialty pharmacy and healthcare industry. 
AscellaHealth has an exciting new strategic alliance with Optime Care. Can you tell our listeners what this partnership means for others in the industry?
AscellaHealth recently came out with some expanded services. Can you explain these new offerings and their benefits for key market segments that AscellaHealth serves?  
In the current healthcare environment, it seems people are lacking customizable options. Can you speak to the flexibility of AscellaHealth’s solutions and how this ultimately serves to enhance outcomes of branded products?
As chief brand officer for AscellaHealth, Mike ensures the success of the widest variety of strategic projects across departmental segments, and other business development initiatives that cultivate opportunities that affect client segments.
With more than 21+ years of specialty pharmacy, pharmaceutical and biotech industry experience, including roles in national and regional managed markets, specialty supply channels, sales management and specialty brand management. Mike offers strategic insight into specialty pharmacy trends, distribution, contracting, reimbursement, and the application of health outcomes and economic evidence to prove value proposition. He is a recognized leader in the specialty pharmaceutical market for developing and implementing key payer and specialty pharmacy agreements that result in documented savings for specialty market segments.
Mike is active in the biotech community and is an advisor/faculty member of the Academy of Managed Care Pharmacy (AMCP) for Specialty Pharmacy Advisory Group & Biosimilars Partnership Forum, NCPDP Specialty Pharmacy Stakeholder Action Group, Faulty Board Member of the American Journal of Managed Care (AJMC) Specialty Pharmacy for ACOs and was 2014 Editorial Board Member for Specialty Pharmacy Times.
He has published abstracts and articles surrounding plasma-based infusion therapy, and managed markets and specialty pharmacy. He has spoken at a variety of seminars and WebEx’s within specialty groups and other industry related settings.
Mike earned a Bachelor of Arts in Business Management and a Certificate in Clinical Research Compliance and Management (CRCM). He has completed programs in leadership development at Harvard University, Brooks Group, Miller Heiman Account Management and MD Anderson Center Cancer Courses.
 
 
Website: https://ascellahealth.com 
Linkedin: https://linkedin.com/company/ascellahealth 

Getting to know Tenax Therapeutics

 
 
Anthony DiTonno CEO of Tenax Therapeutics, a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs joins eHealth Radio and the Health News and Pharmaceutical Channels.
Listen to interview with host Eric Michaels & guest Anthony DiTonno discuss the following:
Can you tell me a bit about yourself and how you got interested in the healthcare and pharmaceutical industry?
What products are in the pipeline?
Could you please tell us about Tenax's HELP study?
Please let us and talk a little about Levosimendan.
Anthony A. DiTonno has served as CEO since 2018 and as a director since December 2011. From 2013 until filling the role as Tenax CEO, Mr. DiTonno served as Chief Executive Officer of Avantis Medical Systems, Inc., a medical device company that develops and manufactures catheter-based endoscopic devices.
From April 2003 until December 2011, Mr. DiTonno was President and Chief Executive Officer of Neurogesx Inc., a biopharmaceutical company based in the San Francisco Bay area (“Neurogesx”). During his time at Neurogesx, Mr. DiTonno also served on its board of directors.
Mr. DiTonno has funded companies through a variety of financial arrangements including private and public financing, partnerships and debt. He has also been successful in gaining regulatory approvals in both the United States and European Union.
Previously, he was Executive Vice President of Marketing and Sales at Enteric Medical Technologies Inc., which was acquired by Boston Scientific Company; President and Chief Executive Officer of Lifesleep Systems, Inc.; and Vice President and General Manager of Olcassen Pharmaceuticals, which was sold to Watson Laboratories.
Early in his career, he held a variety of positions of increasing responsibility at Rorer Group, Inc. (Rhône Poulenc Rorer) and Wyeth Laboratories. Mr. DiTonno received an M.B.A. from Drexel University and a B.S. in Business Administration from St. Joseph’s University.
 
 
Website: www.tenaxthera.com